Table 5.
Characteristics of patients treated with hepatic arterial infusion of paclitaxel with stable disease
| Patient no. | Age/sex | PS | Paclitaxel mg/m2 | No. of prior Rx | No. of cycles | Type of cancer | Reason off-protocol comments | Progression-free survival, months |
|---|---|---|---|---|---|---|---|---|
| 3 | 43/F | 1 | 150 | 4 | 2 | Breast | Biliary abscess | 2.0 |
| 6 | 71/M | 1 | 175 | 3 | 4 | Colorectal | PD | 4.0 |
| 10 | 67/F | 0 | 225 | 3 | 2 | Breast | Tumor markers increased | 2.1 |
| 14 | 35/F | 1 | 250 | 7 | 4 | Thyroid | Tumor markers increased | 7.1 |
| 27 | 59/M | 0 | 225 | 3 | 3 | Hepatocellular | No evidence of PD | 22.2+ |
N/A non-applicable; PD progressive disease; PS performance status; SD stable disease